A study in people with diabetes.

Recruiting now. Registry record last updated January 15, 2025.

Who can join: Adults 18+, have diabetes.
What you take: Check ClinicalTrials.gov for this trial's study groups and what each group receives.
How long it lasts: The full study runs about 2.3 years; your own time in it is usually shorter.
What you get: Many clinical trials pay for the study medication and the study visits. Some also pay for travel. Ask the study team what this one covers before you sign the consent form.

This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.

Check my fit →

Phase Not ApplicableSponsor Abbott Diabetes CareDrug investigational drugClass OtherSites 2 USEnrollment target 800

What this study is for

Primary condition: Diabetes Mellitus.

Full scientific study title: Prolongation of GLP-1 Adherence When Using Continuous Glucose Monitoring.

Who can join

Age18 and upSexAny

Adults 18+, have diabetes. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

Subject must be at least 18 years of age.
Subject must be able to read and understand English.
Subject must have a type 2 diabetes diagnosis.
In the investigator's opinion, subject must meet the criteria for beginning use of GLP-1 or GIP/GLP-1 medications for management of their diabetes.
Subject is beginning use of GLP-1 / GIP/GLP-1 medication for management of their diabetes.

Key exclusion criteria

Subject is a member of the Study Staff.
Subject has a diagnosis of type 1 or gestational diabetes.
Subject is currently using or has previously used GLP-1 or GIP/GLP-1 drugs for any reason.
Subject is currently using a Continuous Glucose Monitor (CGM) as their standard of care device to manage their diabetes.
Subject has known allergy to medical grade adhesive, isopropyl alcohol and/or ethyl alcohol used to disinfect skin.

Where this trial is enrolling

This trial has 2 sites across 1 state. Contact a site coordinator directly to start screening.

Florida2 sites

East Coast Institute for Research, LLC
Jacksonville, Florida
Rebecca Goldfaden, Pharm D904-854-1354rg@eastcoastresearch.net
Excellence Medical and Research
Miami Gardens, Florida
Alexander Martinez, OD786-320-5229amartinez@emrclinic.com

Follow this trial

We email you if NCT06668935 changes status, adds new sites in your state, or if a similar trial opens for the same condition. No spam, opt out any time.

Timeline

Started enrolling: October 24, 2024. Expected completion: January 2027. Last updated on ClinicalTrials.gov: January 15, 2025.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked August 21, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site · LinkedIn · Contact

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.